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ABSTRACT
The question of whether cancer stem/tumor-initiating cells
(CSC/TIC) exist in human melanomas has arisen in the
last few years. Here, we have used nonadherent spheres
and the aldehyde dehydrogenase (ALDH) enzymatic activ-
ity to enrich for CSC/TIC in a collection of human mela-
nomas obtained from a broad spectrum of sites and
stages. We find that melanomaspheres display extensive in
vitro self-renewal ability and sustain tumor growth in
vivo, generating human melanoma xenografts that recapit-
ulate the phenotypic composition of the parental tumor.
Melanomaspheres express high levels of Hedgehog (HH)
pathway components and of embryonic pluripotent stem
cell factors SOX2, NANOG, OCT4, and KLF4. We show
that human melanomas contain a subset of cells expressing
high ALDH activity (ALDHhigh), which is endowed with
higher self-renewal and tumorigenic abilities than the
ALDHlow population. A good correlation between the
number of ALDHhigh cells and sphere formation efficiency
was observed. Notably, both pharmacological inhibition
of HH signaling by the SMOOTHENED (SMO) antagonist
cyclopamine and GLI antagonist GANT61 and stable
expression of shRNA targeting either SMO or GLI1
result in a significant decrease in melanoma stem cell
self-renewal in vitro and a reduction in the number of
ALDHhigh melanoma stem cells. Finally, we show that
interference with the HH-GLI pathway through lentiviral-
mediated silencing of SMO and GLI1 drastically dimin-
ishes tumor initiation of ALDHhigh melanoma stem cells.
In conclusion, our data indicate an essential role of the
HH-GLI1 signaling in controlling self-renewal and tumor
initiation of melanoma CSC/TIC. Targeting HH-GLI1 is
thus predicted to reduce the melanoma stem cell compart-
ment. STEM CELLS 2012;30:1808–1818
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INTRODUCTION
Melanoma is the most aggressive and lethal among skin
cancers, known for its high metastatic potential, enhanced
heterogeneity, and resistance to chemotherapy. Prognosis for
patients with advanced metastatic melanoma remains poor,
with a median survival time of 6–9 months and a 3-year sur-
vival rate of only 10%–15% [1]. Adjuvant therapy with
IFNalpha, recommended after resection of primary melano-
mas with lymph node metastases, provides modest disease-
free survival [2]. The conventional drugs used for metastatic
melanomas produce only transient responses [3]. Recent clini-
cal trials using the BRAF (v-raf murine sarcoma viral onco-
gene homolog B1) inhibitor Vemurafenib [4] and the mono-
clonal antibody against CTLA-4 Ipilimumab [5] have shown
better therapeutic responses, although resistance mechanisms
and severe adverse effects have already been described (e.g.,
6–9).
Several types of human cancer have been shown to con-
tain a subset of cells endowed with tumorigenic potential and
stem cell properties, that is the ability to self-renew and to
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give rise to differentiated progeny. These cells, called cancer
stem cells (CSC) or tumor-initiating cells (TIC), are proposed
to drive tumor initiation and progression as well as therapy
resistance [10–12]. It has been suggested that CSC/TIC might
exist in melanoma, but their identity and frequency are still
debated [13]. Several markers have been used to prospectively
isolate stem subpopulations in melanomas, including CD20, a
combination of CD133 and ABCG2, ABCB5, MDR1, and
CD271, or high aldehyde dehydrogenase (ALDH) activity
[14–20]. However, two recent studies using a severely immu-
nocompromised mouse model suggested high frequency of
TIC in melanoma [21, 22]. These studies failed to find any
correlation between a specific phenotype and tumor-initiating
ability and led to questioning the existence of melanoma stem
cells [21, 22]. Thus, it remains unanswered whether tumor
maintenance is sustained by each individual melanoma cell or
only by a distinct subpopulation of cells. In the latter sce-
nario, the elucidation of molecular signaling driving self-
renewal and tumorigenicity of CSC/TIC would be critical in
order to find ways to eradicate them.
The Hedgehog-GLI (HH-GLI) pathway is an intercellular
signaling playing a role in determining proper embryonic pat-
terning and cell fate during development [23]. Secreted HH
ligands initiate signaling in receiving cells by binding and
inactivating the transmembrane receptor PATCHED1
(PTCH1), which relieves its inhibition on the transmembrane
protein SMOOTHENED (SMO). As a consequence, active
SMO initiates an intracellular cascade that leads to the activa-
tion of the three GLI (zinc finger) transcription factors [24].
Transcriptional activation is mostly effected by GLI1 and
GLI2, whereas GLI3 shows mainly repressor activity in the
absence of ligands. In physiological conditions, Sonic Hh pro-
motes the development of multipotent neural crest progenitors
[25], from which melanocytes derive, and regulates prolifera-
tion of human melanocytes [26]. Similarly, it regulates brain
stem cell lineages (e.g., 27–30) and skin stem cells (e.g., 31,
32). Aberrant activation of the HH-GLI signaling has been
demonstrated in several types of human cancers [33]. The
HH-GLI pathway is active and required for melanoma prolif-
eration and xenograft growth in vivo [26] and GLI2 has been
shown to drive melanoma invasion and metastasis [34]. HH-
GLI signaling also regulates CSC survival and expansion in
several types of cancer, such as glioma, colon, and gastric
cancer, multiple myeloma, and myeloid leukemia [35–39].
In this study, we have isolated a population of human
melanoma cells endowed with stem cell properties and high
tumorigenic potential. We report that blockade of the HH-
GLI pathway in melanoma stem cells, through chemical and
genetic inhibition of SMO and GLI1, effectively reduces their
self-renewal and tumor-initiation ability.
MATERIALS AND METHODS
Human Melanomas, Primary Cultures, and
Melanomaspheres
A375 melanoma cells (CRL-1619) were obtained from ATCC
(Manassas, VA, http://www.lgcstandards-atcc.org) and grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Euroclone, Mi-
lan, Italy, http://www.euroclonegroup.it) with 10% fetal bovine
serum (FBS). Mycoplasma was periodically tested by 4’,6-diami-
dino-2-phenylindole inspection and PCR. Melanoma samples
were obtained from patients of the Plastic Surgery Unit of the
S.M. Annunziata Hospital (Florence, Italy) and Dermatology
Department and Medical-Surgical Critical Area of the University
of Florence (Florence, Italy) after approved protocols by the
Ethics Committee. Tumors were incubated for 1 hour at 37C
with 1 mg/ml collagenase A and 20 lg/ml DNase I (Roche
Applied Science, Basel, Switzerland, http://www.roche-applied-
science.com) in DMEM/F12 (Euroclone). After dissociation and
filtration, cells were grown in DMEM/F12 with 10% FBS and
epidermal growth factor (EGF) (5 ng/ml) (Invitrogen, Carlsbad,
CA, http://www.invitrogen.com) as already described [26]. Short-
term cultures were obtained from 23 melanomas, of which two
were from primary and 21 from metastatic melanomas (Table 1).
SSM2c, M15c, and M26c cultures were cloned from the original
metastases (SSM2, M15, and M26, respectively) by plating one
cell per well. Patient-derived melanomas were passaged one to
two times prior to RNA extraction and in vitro experiments. The
expression of melanoma markers was verified on adherent cells
by immunocytochemistry using anti-Melan A, anti-S100, and
anti-Vimentin antibodies. For melanoma-sphere cultures, cells
were seeded at a concentration of 5,000 cells per milliliter either
in DMEM/F12 serum-free medium with N2 supplement, 20 lg/
ml insulin, 10 ng/ml EGF, and 10 ng/ml basic fibroblast growth
factor (bFGF) (Invitrogen) or in human embryonic stem cell me-
dium (hESCM), as previously reported [14, 40].
RNA Interference and Lentivectors
Lentiviruses were produced in HEK-293T cells as already
described [41]. Lentiviral vectors pLKO.1-puro (LV-c), pLKO.1-
puro-shSMO-64 (LV-shSMO-64) (targeting sequence 50-GTGGA-
GAAGATCAACCTGTTT-30), pLKO.1-puro-shSMO-65 (LV-
shSMO-65) (targeting sequence 50-CCTGATGGACACAGAACT-
CAT-30), pLKO.1-puro-shGLI1-85 (LV-shGLI1-85) (targeting
sequence 50-CCTGATTATCTTCCTTCAGAA-30), and pLKO.1-
puro-shGLI1-87 (LV-shGLI1-87) (targeting sequence 50-
CCAAACGCTATACAGATCCTA-30) were from Open Biosys-
tem (Lafayette, CO, https://www.openbiosystems.com). Most of
the experiments have been performed using LV-shSMO-64 and
LV-shGLI1-85.
Self-Renewal Assay and Treatments
For self-renewal assay, melanomaspheres were dissociated and
plated in 96-well plates at one cell per well or in 12-well plates
at one cell per microliter dilutions. Cyclopamine (TRC, Toronto,
Canada, http://www.trc-canada.com) (5 and 10 lM) [42] and to-
matidine (10 lM) treatments were performed for 7 days,
GANT61 treatment (Sigma, St. Louis, MO, http://www.sigmaal-
drich.com) (0.5, 1, and 2.5 lM) [43] was carried out for 3 days
in DMEM/F12 or hESCM medium containing 2 ng/ml EGF and
bFGF. After treatment, spheres were dissociated, counted, and
plated for self-renewal assay without the drugs. After 1 or 2
weeks, spheres were counted. All the experiments were per-
formed in triplicate and were repeated at least three times.
Aldefluor Assay and Flow Cytometry
The Aldefluor kit (Stem Cell Technologies, Vancouver, Canada,
http://www.stemcell.com) was used to profile and separate cells
with high and low ALDH activity (ALDHhigh and ALDHlow), fol-
lowing manufacturer’s protocol. Dissociated cells were incubated
in Aldefluor assay buffer containing the ALDH protein substrate
for 30 minutes at 37C. Sorting gates for fluorescence-activated
cell sorting (FACS) were drawn relative to cell baseline fluores-
cence, which was determined by the addition of the ALDH-spe-
cific inhibitor diethylaminobenzaldehyde (DEAB) during the
incubation. DEAB-treated samples served as negative controls.
Cells derived from xenografts were resuspended in Aldefluor
buffer for the subsequent staining with the phycoerythrin-labeled
monoclonal TRA-1-85 (BD Bioscience, San Diego, CA, http://
www.bdbiosciences.com), which recognizes human cells and thus
enables us to distinguish human from mouse cells. Nonviable
cells were identified by propidium iodide staining. Flow cytome-
try was performed on a FACSCanto II (BD Bioscience). Cells
were sorted by a FACS Aria (BD Bioscience) and the purity of
sorted cells was assayed after the sorting was completed.
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Immunocytochemistry and In Situ Hybridization
Formalin-fixed paraffin-embedded sections were subjected to
immunocytochemical staining with mouse anti-human ALDH1
(clone 44/ALDH) (BD Biosciences, 611194) [44] and rabbit
anti-human SMO (Abcam, Cambridge, U.K., Ab38686, http://
www.abcam.com) antibodies. Briefly, after deparaffinization/
hydratation and antigen retrieval, performed with citrate buffer
pH 6.0, slides were incubated with the primary antibody fol-
lowed by incubation with a secondary antibody and visualiza-
tion using AEC (Invitrogen) for ALDH1 or UltraVision Detec-
tion System (Lab Vision, Fremont, CA) and diaminobenzidine
(DAB) (Dako, Carpinteria, CA, http://www.dako.com/) for
SMO, according to manufacturer’s recommendations. For GLI1
immunofluorescence, melanomaspheres were fixed with 4%
formaldehyde, permeabilized with 0.1% Triton X-100 in phos-
phate buffered saline (PBS), blocked with 10% goat serum, and
incubated with rabbit anti-GLI1 antibody (Abcam, Ab49314)
and an anti-rabbit FITC secondary antibody. In situ hybridiza-
tion with digoxygenin-labeled antisense RNA probe for GLI1
was as previously described [26].
Quantitative Real-Time PCR
Total RNA was isolated with TriPure Isolation Reagent (Roche
Applied Science), subjected to DNase I treatment (Roche Applied
Science), and checked for integrity. Reverse transcription was
performed with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Carlsbad, CA, http://www.appliedbiosys-
tems.com). Quantitative real-time PCR (qRT-PCR) amplifications
were carried out at 60C using Power SYBR Green PCR Master
Mix (Applied Biosystems) on a 7500 Fast Real-Time PCR Sys-
tem (Applied Biosystems) and analyzed by d-Ct method using
glyceraldehyde 3-phosphate dehydrogenase and b-ACTIN as
housekeeping genes. Primer sequences are listed in supporting in-
formation Table S1.
Western Blot
Western blot was carried out as previously described [41]. Anti-
bodies used were rabbit polyclonal anti-GLI1 (Abcam, Ab49314),
rabbit polyclonal anti-SMO (Abcam, Ab38686), mouse anti-
ALDH1 (BD Biosciences), and anti-HSP90 (Heat Shock Protein
90) (Santa Cruz Biotechnology, Santa Cruz, CA, http://scbt.com).
Chemiluminescent detection was used.
Mouse Xenografts of Human Melanomas
In vivo experiments were conduced in accordance with National
Guidelines and approved by Ethical Committee of Animal Welfare
Office of Italian Health Ministry. Six- to eight-week-old female
athymic nude mice (Foxn1 nu/nu) (Harlan Laboratories, Indianapo-
lis, IN, http://www.harlan.com) were injected subcutaneously (s.c.)
in lateral flanks with 10, 102, and 103 cells from SSM2c spheres;
103 FACS-sorted ALDHhigh and ALDHlow SSM2c cells; 103
FACS-sorted ALDHhigh SSM2c cells transduced with either
pLKO.1-puro, pLKO.1-puro-shSMO, or pLKO.1-puro-shGLI1 len-
tiviruses. Cells were resuspended in Matrigel (BD Biosciences)/
DMEM (1/1) before inoculation. Animals were monitored daily,
subcutaneous tumor size was measured every 2–3 days by a cal-
liper, and tumor volumes were calculated using the formula V ¼W2
 L  0.5, where W and L are tumor width and length, respectively.
Statistical Analysis
Data are presented as means 6 SEM from at least three inde-
pendent experiments. Statistical analysis of the data was
Table 1. Clinical features of melanomas used in this study and percentage of ALDHhigh cells
Patient sample Gender/age Type Site Location Breslowa Stage Sphere %ALDHhigh cells Follow up
SSM1 M, 55 MM Skin Trunk 8.5 IIIB 25.5 Deceased
SSM2 M, 55 MM Skin Trunk 8.5 IIIB þ 42
SSM2c þ 51.9
M2 M, 66 MM LN Armpit 0.4 IIIC  4.9 Alive
M3L F, 84 MM LN Groin 6.4 IIIC  6.7 Alive
M3R LN Groin IIIC þ 8.8
M5 M, 65 MM Skin Arm 1.1 IIIB þ 9.8 Alive
M6 M, 79 MM LN Arm N/A IIIC  3.4 Alive
M8 F, 59 MM LN Groin 6.9 IV  2.8 Alive
M9 F, 74 MM Skin Arm N/A IV  1.8 Alive
M11 M, 76 MM Skin Trunk 9.3 IIIC  4 Alive
M13 M, 44 MM Pancreas N/A N/A IV  2 Alive
M14 F, 79 MM Skin Leg 8.1 IIIC þ 20.5 Alive
M15 M, 85 MM Skin Scalp 11 IIC N/A N/A Deceased
M15c þ 46.8
M16 M, 88 PM Cheek 10 IIB þ 19.8 Alive
M17P M, 80 PM Trunk i.s. regr IVb  6 Alive
M17M M, 80 MM Skin Clavear region i.s. regr IVb  2.2
M20 N/A MM Skin Scalp 11 IVa  N/A Alive
M21 M, 87 MM Skin Trunk 5 IIIC þ 44 Alive
M22 F, 80 MM Skin Arm 2.6 IIIC  N/A Deceased
M25 Skin Leg IV  2.6
M26 F, 79 MM LN Groin 0.47 IV 6.9 Alive
M26c þ 36.6
M27 M, 71 MM LN Groin 1.2 IV þ 10.9 Alive
M28 M, 82 MM LN Armpit 2.35 IIIC  5 Alive
A375 Cell line þ 28
aThickness (mm) of the primary melanoma from which metastasis originated. i.s. regr: melanoma in situ with marker regression. N/A: data
not available/not performed. SSM1 and SSM2 were two skin metastases that were excised from the same individual 1 and 4 months after
diagnosis, respectively. M3L and M3R were two LN metastases excised from the same patient from a bilateral inguinal lymphadenectomy.
M17P and M17M were a primary and metastatic melanomas, respectively, excised form the same individual. M22 and M25 were two skin
metastases from the same patient, excised 1 and 5 months after diagnosis, respectively. SSM2c, M15c, and M26c were cloned from the
original metastases (SSM2, M15, and M26, respectively).
Abbreviations: ALDH, aldehyde dehydrogenase; LN, lymph node; MM, metastatic melanoma; PM, primary melanoma.
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performed by two-tailed Student’s t test. p values of .05 were
considered statistically significant.
RESULTS
Melanomaspheres Display Stem Cell-Like Features
and Tumor-Initiation Ability
Growth of melanoma cells as spheres in human embryonic or
neural stem cell media has been shown to support the selec-
tion of self-renewing cells enriched in CSC/TIC [14, 15, 45].
Two primary and 21 metastatic melanomas, of which 12 skin,
eight lymph node, and one pancreas metastases, were used
(Table 1). Melanomasphere cultures were established from
metastatic melanomas SSM2c, M3R, M5, M14, M15c, M16,
M21, M26c, and M27 and the melanoma cells A375 (Table 1
and Fig. 1A). Self-renewal ability of melanomaspheres was
assessed by dissociating primary spheres to single cell and
growing them at clonal density of one cell per microliter or at
limiting dilution (one cell per well). Single melanomasphere
cells generated secondary clones that could be redissociated
and regenerate new spheres from single cells for at least 10
passages (Fig. 1B). All short-term cultures expressed S100 or
Melan-A (supporting information Fig. S1) and the melano-
cyte-specific microphthalmia-associated transcription factor
(MITF-M) mRNA (supporting information Fig. S2), demon-
strating their melanogenic origin. qRT-PCR analysis showed
that expression levels of embryonic stem cell pluripotency factors
SOX2, NANOG, OCT4, and KLF4 and the stem cell marker
ALDH1 isoform A1 were high in melanomaspheres (Fig. 1C).
Tumorigenicity of melanomaspheres was assessed by
evaluating their capacity to form tumors when s.c. injected
into athymic nude mice. At a dose of 103 cells, 100% of the
injection sides generated primary tumors (Fig. 1D and sup-
porting information Fig. S3). Notably, SSM2c cells could
form tumors when as few as 10 cells were injected (Fig. 1D,
1E). Melanomaspheres could be rederived from the xenotrans-
planted tumors and they could form secondary tumors, which
developed in 100% of the injected mice and grew faster than
their corresponding first passage (Fig. 1D). Human melanoma
xenografts generated from melanomaspheres in nude mice
closely resembled the histological features of the primary tu-
mor from which they were derived (Fig. 1F, 1G). Altogether,
these results indicate that cells from melanomaspheres have
self-renewal ability, express high levels of embryonic stem
cell pluripotency factors, and are able to sustain tumor growth
in vivo, suggesting that melanomaspheres possess the funda-
mental properties of CSC.
Human Melanomas Contain a Population
with High ALDH Activity
It has been shown that cells with high ALDH activity (ALDH-
high) are enriched in CSC in a variety of tumor types [44, 46–
48], including melanoma [20]. We used the Aldefluor assay to
quantify the percentage of ALDHhigh cells in two primary mela-
nomas and 19 melanoma metastases, of which 10 from skin,
eight from lymph nodes, and one from pancreas. A percentage
of ALDHhigh cells, ranging from 1.8% to 51.9% of the total via-
ble cells, was detected by flow cytometry in all the melanomas
tested (Table 1 and Fig. 2A). Interestingly, skin metastases
showed the highest percentage of ALDHhigh cells (>10%),
compared to lymph node and pancreas metastases (Fig. 2B).
Our analysis shows that only tumors with a percentage of
ALDHhigh cells near to 10% or higher formed spheres in culture
(Table 1), suggesting a good correlation between ALDHhigh ac-
tivity and spheres formation efficiency. qRT-PCR analysis
showed a positive correlation between the percentage of ALDH-
high cells and NANOG expression (R2 ¼ 0.71) (Fig. 2C), sug-
gesting an abundance of CSC in this population.
To examine the relationship between ALDH expression
and clinical malignant melanoma progression and to assess its
potential use as a marker for melanoma stem cells, we ana-
lyzed ALDH1 expression by immunocytochemistry in four
major diagnostic types: 10 normal and 10 dysplastic/atypical
melanocytic nevi, 10 thin (<1 mm) and 10 thick (>1 mm)
primary melanomas, and 10 metastatic melanomas. We found
Figure 1. Human melanoma cells grown as spheres display stem
cell-like features and tumorigenic ability. (A): Patient-derived adherent
melanoma cells (SSM2c, M14, and M21) (left panels) form floating
spheres (right panels) under serum-free conditions (scale bar ¼ 100
lm). (B): Growth of melanomasphere cultures. Total cell number is
reported over 10 passages. (C): Quantitative real-time PCR (qRT-PCR)
analysis of stem cell marker transcripts in patient-derived melanoma
cells (SSM2c, M14, M21, and M26c) and A375 cell line. qRT-PCR val-
ues reflect Ct values after normalization with two housekeeping genes
and are shown as fold change in spheres versus monolayer. (D):
Tumorigenic potential of melanomaspheres. Growth curves of primary
(first passage) and secondary (second passage) melanoma xenografts,
generated by injection of different doses of melanomaspheres-derived
SSM2c cells (n ¼ 8 for each group). (E): Representative pictures of a
subcutaneous tumor (scale bar ¼ 5 mm). (F, G): H&E staining of a
melanoma from SSM2 patient (F) and from a melanoma xenograft in
mouse derived from SSM2c spheres (G) (scale bar ¼ 100 lm). Abbre-
viation: ALDH1A1, aldehyde dehydrogenase 1 isoform A1.
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that primary and metastatic melanomas contained more cells
expressing ALDH1 than normal and dysplastic melanocytic
nevi. Nevi showed only few positive cells (Fig. 2D and sup-
porting information Table S2) and weak dermal staining in
the microvasculature, hair follicles, and sebaceous glands
(data not shown), as previously reported [49]. We also
detected more ALDH1-positive cells in thick primary melano-
mas and melanoma metastases than in thin primary melano-
mas (Fig. 2D and supporting information Table S2). Notably,
in most of the primary melanomas, ALDH1 was highly
expressed in tumor cells at the tumor-host interface (Fig. 2E),
suggesting that the ALDH1-positive cells might be mainly
localized at the invading tumor front. ALDH1 was expressed
in all thick primary and metastatic melanomas, with ALDH-
high cells representing approximately 5% to 50%–60% of tu-
mor cells (Fig. 2F, 2G, supporting information Table S2),
consistent with cytometric Aldefluor analysis.
Enhanced Self-Renewal and Tumorigenicity of
ALDHHigh Melanoma Cells
To determine whether the subset defined by high ALDH ac-
tivity (ALDHhigh) was enriched in CSC/TIC, we compared
the ability of FACS-sorted ALDHhigh versus ALDHlow mela-
noma cells to self-renew in vitro and to initiate tumor forma-
tion in vivo, using SSM2c and A375 cells. Self-renewal assay
showed that ALDHhigh cells produced more spheres than the
ALDHlow population (Fig. 3A, 3B). Gene expression analysis
revealed that ALDHhigh population expressed higher level of
stem cell markers SOX2, OCT4, and NANOG than the ALDH-
low population (Fig. 3C). These data indicate that ALDHhigh
melanoma cells display a stemness signature and have higher
self-renewal ability than ALDHlow melanoma cells. We next
investigated the activation of the HH pathway in both subpo-
pulations. GLI1 is one of the final effectors of the HH path-
way and the best read out of an active pathway [50]. Recent
reports suggest that in several types of cancer, including mel-
anomas, GLI1 can be modulated by proliferative and onco-
genic inputs, in addition to or independent of upstream HH
signaling [24, 26, 51–54]. Therefore, we compared the expres-
sion of GLI1 protein in ALDHhigh and ALDHlow cells. Western
blot analysis revealed that ALDHhigh cells expressed higher level
of GLI1 as compared to the ALDHlow population (Fig. 3D).
To test the tumorigenicity of the ALDHhigh subpopulation,
103 isolated ALDHhigh and ALDHlow cells from SSM2c and
A375 spheres were injected s.c. into athymic nude mice. The
tumors generated from ALDHhigh of both SSM2c (Fig. 3E,
3F) and A375 cells (supporting information Fig. S4) were sig-
nificantly larger and grew faster than tumors originated from
ALDHlow cells. Western blot analysis of SSM2c xenografts,
dissected 38 days after the injection, showed higher expres-
sion of GLI1 protein in tumors derived from ALDHhigh cells
than in those from ALDHlow cells (Fig. 3G), suggesting that
ALDHhigh cells maintain high HH pathway activity in vivo.
Consistently, in situ hybridization analysis confirmed that
tumors derived from ALDHhigh cells presented higher level of
GLI1 mRNA than those derived from ALDHlow cells (sup-
porting information Fig. S5).
We next compared the ability of ALDHhigh and ALDHlow
cells to re-establish tumor heterogeneity. Primary tumors were
harvested and reanalyzed both by the Aldefluor assay to
elucidate their ALDH phenotype after in vivo growth and
by anti-human TRA-1 antibody to distinguish human cells.
Reanalysis of tumors produced from sorted ALDHhigh tumor
cells revealed a mixed population that contained 6.5% of
ALDHhigh/hTRAþ cells. In contrast, ALDHlow tumors were
found to possess only a very small residual ALDHhigh/hTRAþ
cell subpopulation (Fig. 3H). This result confirms higher abil-
ities of the ALDHhigh cells to re-establish tumor heterogeneity
in vivo, consistently with the existence of a cellular hierarchy
in melanomas with respect to ALDH.
Inhibition of HH-GLI Signaling Decreases
Self-Renewal of Melanoma Stem Cells
The ALDHhigh phenotype is associated with high HH activity,
enhanced self-renewal and tumorigenicity, consistent with the
idea that ALDHhigh population is enriched in melanoma stem
Figure 2. Human melanomas contain cells with high ALDH activ-
ity. (A): Flow cytometry analysis of two representative patient-
derived metastatic melanomas (M14 and M5) using the Aldefluor
assay. Baseline fluorescence was established by inhibiting ALDH ac-
tivity with DEAB (left) and used to generate a gate that will identify
ALDHhigh cells in melanoma cells incubated without DEAB (right).
(B): Percentage of ALDHhigh cells in skin (n ¼ 10), lymph node (n ¼
8), and pancreas (n ¼ 1) metastases, determined by flow cytometry.
(C): Linear correlation analysis between NANOG expression, meas-
ured by quantitative real-time PCR, and ALDH activity, measured by
flow cytometry, shows a positive correlation between NANOG expres-
sion and the percentage of ALDHhigh cells. (D): Quantification of the
percentage of ALDH1-positive cells in melanocytic nevi (n ¼ 10),
dysplastic nevi (n ¼ 10), thin (n ¼ 10) and thick (n ¼ 10) primary
melanomas, and melanoma metastases (n ¼ 10), as determined by
immunocytochemistry. Red crosses indicate outliner values. (E-G):
ALDH1 immunocytochemistry in a primary melanoma (E), a lymph
node (F), and a skin metastases (G). Note the localization of ALDH-
positive cells in the tumor-normal tissue interface (E). Scale bar ¼
200 lm (E) and 60 lm (F, G). Abbreviations: ALDH, aldehyde dehy-
drogenase; DEAB, diethylaminobenzaldehyde; LN, lymph node.
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cells. To test whether HH-GLI function is involved in mainte-
nance of the ALDHhigh melanoma cells, we inhibited the HH
pathway by knocking down SMO. Silencing of SMO was
achieved by two independent shRNAs expressed from replica-
tion of incompetent puromycin-resistant lentivectors: shSMO-
64 and shSMO-65 (supporting information Fig. S6). FACS
analysis revealed a drastic decrease in the fraction of ALDH-
high cells (from 52.6% to 2.5%) in SSM2c cells transduced
with shSMO (Fig. 4A). Western blot analysis showed that
silencing of SMO in SSM2c cells led to a loss of endogenous
SMO and GLI1 proteins (Fig. 4B), confirming the efficient in-
hibition of these HH components. To further assess the role
of the transcription factor GLI1 itself in maintaining the
ALDHhigh melanoma stem cells, we silenced specifically
GLI1, using two independent shRNA: shGLI1-85 and
shGLI1-87 (supporting information Fig. S7). FACS analysis
revealed a smaller population of ALDHhigh cells in SSM2c
transduced with shGLI1 (from 52.6% to 15.4%) (Fig. 4A),
consistent with the results obtained by inhibiting SMO. GLI1
silencing resulted in an efficient inhibition of endogenous
Figure 3. ALDHhigh human melanoma cells exhibit enhanced self-renewal and tumorigenicity and harbor active Hedgehog pathway. (A):
Sphere formation efficiency of fluorescence-activated cell sorting (FACS)-sorted ALDHhigh and ALDHlow SSM2c and A375 cells *, p < .05. (B):
Representative pictures of ALDHhigh and ALDHlow SSM2c spheres (scale bar ¼ 50 lm). (C): Gene expression analysis of ALDHhigh SSM2c
cells, as measured by quantitative real-time PCR. Ct values were normalized with the average of the values of two housekeeping genes and
shown as ALDHhigh/ALDHlow ratios. (D): Western blot of FACS-sorted ALDHlow and ALDHhigh SSM2c cells showing the expression level of
ALDH1 and GLI1 proteins. HSP90 was used as control. (E): Tumor growth curves were generated from 103 FACS-sorted ALDHhigh and ALDH-
low SSM2c cells (n ¼ 12 for each group) *, p < .05. (F): Representative images of (E) (scale bar ¼ 10 mm). (G): Western blot of tumors derived
from ALDHlow and ALDHhigh cells showing endogenous levels of ALDH1, GLI1, and SMO proteins. HSP90 is used as control. (H): ALDH ac-
tivity was assayed in tumors derived from ALDHhigh and ALDHlow cells, with DEAB-treated cells used as a negative control. Cells were at the
same time analyzed with anti-human TRA-1 antibody, to allow the discrimination from mouse cells. It shows that ALDHhigh tumors possess a
greater proportion of ALDHhigh cells (6.5%) than ALDHlow tumors (0.4%). Abbreviations: ALDH, aldehyde dehydrogenase; DEAB, diethylami-
nobenzaldehyde; GLI1, GLI family zinc finger 1; SMO, SMOOTHENED.
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GLI1, as indicated by the complete loss of GLI1 protein in
SSM2c cells (Fig. 4B). We next assessed the effect of HH
pathway inhibition on self-renewal ability. Silencing of SMO
and GLI1 reduced self-renewal of ALDHhigh melanoma cells
(p  .001) and, at lesser extent, that of ALDHlow melanoma
cells (p  .05) (Fig. 4C). This result correlates with the
higher expression of GLI1 in ALDHhigh population (Fig. 3D).
Altogether, these findings indicate that ALDHhigh cells are
more sensitive to SMO and GLI1 inhibition than ALDHlow
cells, suggesting a dependence on HH-GLI activity for sur-
vival and self-renewal.
As an alternative approach to test the involvement of the
HH pathway in melanoma stem cells, we have used melano-
masphere cultures, which self-renew and mimic the original
tumor after transplantation into athymic nude mice (Fig. 1F,
1G). GLI1 is highly expressed in melanomaspheres with a
prevalent nuclear localization, as shown by immunofluores-
cence (Fig. 5A). qRT-PCR analysis showed that also SHH,
PTCH1, SMO, GLI2, GLI3 and the targets HIP1 and vascular
endothelial growth factor A were highly expressed in melano-
maspheres (supporting information Fig. S8). To test for a role
of HH-GLI signaling in regulating melanomasphere self-
renewal, we knocked down SMO and GLI1. Silencing of
SMO diminished the number of A375 and SSM2c spheres by
75% and 70%, respectively (Fig. 5B, 5D). Self-renewal assay
showed that GLI1 silencing reduced the number of A375 and
SSM2c secondary clones by 48% and 64%, respectively (Fig.
5C, 5D). Western blot analysis showed that silencing of SMO
and GLI1 in melanomaspheres completely knocked down
GLI1 protein (Fig. 5E, upper panel) and GLI1 and SMO
mRNA levels (Fig. 5E, lower panel). As an additional test to
investigate the requirement of HH-GLI function, we also
inhibited SMO pharmacologically by treatment with cyclop-
amine, a plant alkaloid [55] that inhibits SMO [42, 56, 57]
and that we found it to be a specific inhibitor of HH-GLI
(e.g., 26, 35, 36, 58). Melanomaspheres were treated for 7
days with cyclopamine [35]. After the treatment, spheres were
dissociated and we quantified the ability of single cells to
generate secondary spheres in absence of the drug. Consis-
tently with silencing of SMO, cyclopamine treatment led to a
significant and dose-dependent reduction of the ability to
form secondary spheres (Fig. 5F). Similarly, chemical inhibi-
tion of GLI1 and GLI2 with GANT61 [43, 59, 60] resulted in
a dose-dependent decrease in spheres number (Fig. 5G). Alto-
gether, these results indicate that SMO and GLI1 are critical
to maintain self-renewal of melanoma stem cells.
To complement these studies, we investigated whether acti-
vation of the HH pathway in adherent cells could enhance the
number of putative melanoma stem cells. FACS analysis showed
that activation of the HH pathway by silencing of PTCH1 [41],
Figure 4. Requirement of Hedgehog-GLI function in ALDHhigh melanoma stem cells. (A): Aldefluor assay of SSM2c cells expressing LV-c,
LV-shSMO, or LV-shGLI1, showing a drastic reduction of ALDHhigh cells after silencing of SMO (LV-shSMO) and GLI1 (LV-shGLI1). (B):
Western blot of SSM2c cells transduced with LV-c control, LV-shGLI1, and LV-shSMO, showing a near loss of GLI1 expression in LV-shGLI1
and LV-shSMO and a reduced SMO expression in LV-shSMO. HSP90 was used as loading control. (C): Number of secondary spheres in ALDH-
high and ALDHlow SSM2c cells after silencing of GLI1 (LV-shGLI1) and SMO (LV-shSMO) (*, p < .05; **, p < .001). Abbreviations: ALDH,
aldehyde dehydrogenase; DEAB, diethylaminobenzaldehyde; GLI1, GLI family zinc finger 1; LV, lentiviral vector; SMO, SMOOTHENED.
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an endogenous inhibitor of SMO, increased the number of A375
ALDHhigh melanoma cells (from 28.5% to 68.9%) and enhanced
their self-renewal (supporting information Fig. S9).
Inhibition of the HH-GLI Pathway Reduces
Tumor-Initiation Ability of ALDHHigh
Melanoma Cells
To test the role of the HH signaling in ALDHhigh melanoma
stem cells in vivo, we engrafted s.c. into athymic nude mice
103 ALDHhigh SSM2c cells transduced with LV-shSMO, LV-
shGLI1, and the control LV-c. Cell transduced with the control
yielded rapidly growing tumors (Fig. 6A). Silencing of SMO
and GLI1 greatly reduced tumor growth (Fig. 6A, 6B). Immu-
nocytochemistry and in situ hybridization analyses of sections
obtained from tumors dissected 30 days after injection showed
a dramatic reduction of SMO protein expression in LV-shSMO
tumors (Fig. 6C) and a decrease in GLI1 mRNA expression in
LV-shGLI1 tumors (Fig. 6C) compared to control sections (LV-
c). These results indicate that the reduction of tumor growth
depends on the specific silencing of SMO and GLI1. Consis-
tently, Western blot analysis confirmed the downregulation of
SMO and GLI1 in LV-shSMO and LV-shGLI1 xenografts com-
pared to the control tumors (LV-c) (Fig. 6D). These data sug-
gest that an active HH signaling is required for growth in vivo
of ALDHhigh melanoma stem cells.
DISCUSSION
In this study, we show that human melanomas contain cells
that resemble the properties of CSC, including the ability to
self-renew, to express high levels of stem cell factors, and to
be tumorigenic in immunocompromised mice. Interestingly,
we find that the HH-GLI pathway is required to maintain self-
renewal and tumor-initiating ability of these putative mela-
noma stem cells.
Our data show that melanomaspheres can be grown with
high efficiency from bulk melanoma cells, and that these cells
display in vitro self-renewal ability and sustain tumor growth
in vivo by serial transplantation assay. Moreover, melanoma-
spheres can generate in vivo melanoma xenografts that reca-
pitulate the phenotypic composition of the parental tumor
from which the cells have been derived. These hallmarks
Figure 5. Genetic and chemical inhibition of HH-GLI pathway reduces self-renewal of melanomaspheres. (A): Confocal images of SSM2c
melanomaspheres after immunolabeling with GLI1 antibody. Nuclei were counterstained with DAPI (scale bar ¼ 10 lm). (B, C): Reduction in
the number of secondary melanomaspheres after silencing of SMO (LV-shSMO) and GLI1 (LV-shGLI1) in A375 and SSM2c cells. (D): Repre-
sentative images of melanomaspheres as indicated in (B) and (C) (scale bar ¼ 150 lm). (E): Western blot (upper panel) and qRT-PCR (lower
panels) analyses of SSM2c spheres transduced with LV-c control, LV-shSMO, and LV-shGLI1, showing the near complete loss of endogenous
GLI1 protein (upper panel) and dramatic reduction of GLI1 and SMO mRNA (lower panels). (F, G): Reduction in the number of secondary
spheres in melanomaspheres treated for 7 days with SMO inhibitor cyclopamine (F) or for 3 days with GANT61 (G), a small-molecule inhibitor
of both GLI1 and GLI2 *, p < .05. Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; GLI1, GLI family zinc
finger 1; GLI2, GLI family zinc finger 2; LV, lentiviral vector; SMO, SMOOTHENED.
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resemble the properties of CSC [14, 15, 45], suggesting that
melanomaspheres represent a good model to investigate mela-
noma stem cell biology. According to our gene expression
analysis, melanomaspheres consistently express high levels of
embryonic stem cell pluripotency factors SOX2, NANOG,
OCT4, and KLF4, the cohort of genes that have been shown
to reprogram normal differentiated cells to pluripotent embry-
onic stem cells [61]. This finding is confirmed by other stud-
ies [45, 62] and suggests a high differentiation potential of
melanoma stem cells.
The aggressiveness of melanoma is due to the presence of
highly tumorigenic populations that confer resistance to con-
ventional therapy and embryonic-like differentiation ability
[63, 64]. Therefore, novel therapeutic strategies that selec-
tively target the most resistant and long-living cells within the
tumor, the melanoma CSC/TIC, are needed. We have previ-
ously shown that human melanomas require HH pathway for
proliferation and survival [26]. Here, we demonstrate for the
first time that the HH-GLI signaling is critical for self-renewal
in vitro and tumor initiation of melanoma stem cells. Func-
tionally, the cell-autonomous modulation of HH-GLI signaling
at the level of the transmembrane protein SMO and of the
transcription factor GLI1 in vitro and in vivo by RNA inter-
ference defines melanoma stem cells as primary targets of
HH-GLI signaling. Our data support the inhibition of HH-GLI
as a promising novel therapeutic strategy for human
melanoma.
Currently, no definitive consensus has been reached on
CSC/TIC phenotype for melanoma, although several studies
clearly support the existence within melanomas either of TIC
endowed with stem cells features [13–20] or slow-cycling
cells sustaining tumor growth [65, 66]. Our functional data on
sorted ALDHhigh and ALDHlow melanoma cells showed that
ALDHhigh cells are more tumorigenic and clonogenic than
ALDHlow cells. In addition, isolated ALDHhigh cells are able
to recapitulate tumor heterogeneity for ALDHhigh and ALDH-
low cells in vitro and in vivo, whereas this ability was much
less in isolated ALDHlow cells, consistently with the existence
of a cellular hierarchy in melanoma with respect to ALDH.
ALDHhigh melanoma cells form fast growing tumors in athy-
mic nude mice, whereas ALDHlow cells are capable of form-
ing very small, slow growing tumors. Further studies are
needed to determine whether this indicates residual CSC ac-
tivity in ALDHlow cells or contamination with some ALDH-
high cells. Nevertheless, our data confirm the usefulness of
ALDH activity to enrich for melanoma stem cells. Our find-
ings are consistent with a previous report showing that ALDH
selects tumorigenic melanoma cells in nonobese diabetic/
severe combined immunodeficient (NOD/SCID) mice [20].
However, the use of a fully immunocompromised NOD/
SCID/IL2rcnull (NSG) mouse model suggested that ALDH ac-
tivity does not select for cells with enhanced aggressive prop-
erties [40]. Because the main difference between NSG and
nude or NOD/SCID mice is the absence of natural killer cells
in NSG mice, the discrepancy between our data and this study
[40] is likely due to the different level of immunocompetence
of the xenotransplant recipients. The latter provides a permis-
sive environment for tumor growth [19], and therefore it is
less representative of the human immune status.
In this study, we show that human melanomas contain a
fraction of cells with high ALDH activity, which varies from
2% to 52%. Skin metastases showed the highest percentage of
ALDHhigh cells (Fig. 2B), as determined by flow cytometry.
According to our immunocytochemical analysis, we detected
more ALDH1-positive cells in metastases (most of which are
from the skin) and thick primary melanomas than in thin mel-
anomas. Interestingly, in most of the thick melanomas,
ALDH1 was highly expressed in tumor cells at the tumor-host
Figure 6. Inhibition of the HH-GLI signaling impairs in vivo growth of ALDHhigh melanoma stem cells. (A): Subcutaneous xenograft growth
curves of FACS-sorted ALDHhigh SSM2c cells transduced with a LV-c control, LV-shGLI1, and LV-shSMO. For each group, 12 tumors were an-
alyzed *, p < .05. (B): Representative images of subcutaneous xenografts in nude mice taken at the same time for each group (scale bar ¼ 10
mm). (C, D): Tumors from the mice in (A) and (B) were analyzed by immunocytochemistry for SMO (C, upper panels), by in situ hybridization
for GLI1 (C, lower panels) and Western blot for GLI1 and SMO proteins (D) (scale bar ¼ 100 lm). HSP90 was used as loading control. Abbre-
viations: GLI1, GLI family zinc finger 1; LV, lentiviral vector; SMO, SMOOTHENED.
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interface (Fig. 2E), suggesting that the ALDH1-positive mela-
noma stem cells might be mainly localized at the invading tu-
mor front. ALDH1-positive cells might therefore be involved
in the formation of metastatic melanoma, whereas less aggres-
sive tumors might originate from other types of melanoma-
initiating cells. Notably, the aggressive biological behavior
demonstrated in mice by isolated ALDHhigh cells and the high
percentages of these cells detected in some rapidly lethal mel-
anomas of our series (e.g., patients SSM2c and M15, which
both died 1.5 year after diagnosis) induce to speculate that
ALDH1 represents a melanoma stem cell marker that might
correlate with a poor prognosis.
Here, we show for the first time that blockade of the HH-
GLI pathway by interference with SMO or GLI1 decreases
self-renewal and tumorigenicity of ALDHhigh melanoma stem
cells. This finding confirms the results obtained with melano-
masphere-derived CSC and suggest that HH-GLI is critical to
maintain ALDHhigh melanoma stem cells. At present, it is
unclear whether high ALDH activity is functionally involved
in stem cells (normal or CSC) or it is only a useful marker to
identify CSC/TIC. Because ALDH enzyme activity is fre-
quently required for the detoxification of intracellular exoge-
nous and endogenous aldehydes, it might protect skin (stem)
cells from xenobiotics and in the meanwhile make them
insensitive to chemotherapeutic agents (e.g., 67).
CONCLUSIONS
Our data support the existence within human melanomas of a
subpopulation made up of highly tumorigenic cells with fea-
tures similar to embryonic stem cells, including extensive
self-renewal and a stemness signature. Whereas several forms
of treatment can give temporary benefits, radical therapy for
melanoma will rely on the ability to eliminate these subpopu-
lations, irrespective of their number. Our study highlights the
role of the HH signaling pathway in driving self-renewal and
tumorigenicity of melanoma stem cells and points to SMO
and GLI1 as novel and effective therapeutic targets for the
treatment of human melanoma.
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